To further assess the efficacy of our TF-PS B vaccine construct, TF-BSA was synthesized and immunological evaluation revealed a substantial decrease in TF specific antibody recognition elicited by TF-BSA compare to TF-PS B. Antibodies from sera in TF-PS B immunized mice bind selectively to TF expressing MCF-7 carcinoma cells as noted in FACS experiments in high degree. The gene discussed is TF; the disease is carcinoma.